US Stock Movement | Biogen rises 3.8% pre-market as its spinal muscular atrophy treatment receives FDA Breakthrough Therapy Designation

Glonghui, June 5｜Biogen (BIIB.US) rose 3.8% pre-market to $204. According to reports, Biogen announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to salanersen for the treatment of spinal muscular atrophy (SMA). The breakthrough therapy designation aims to accelerate the development and review process of drugs for serious diseases, provided that preliminary clinical evidence indicates the drug may demonstrate substantial improvement over existing therapies on clinically significant endpoints. Salanersen is a novel antisense oligonucleotide (ASO) under development and is expected to deliver highly effective results in SMA treatment with an annual dosing regimen.